A Phase 1 interventional study of Ponsegromab and Ponsegromab in Healthy, sponsored by Pfizer. Completed at 2 sites in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this clinical trial is to learn about the safety of the study medicine (ponsegromab) and how it undergoes change and elimination in healthy Chinese adults. This study is seeking male and female Chinese participants who are very healthy as confirmed after some medical tests.
All participants in this study will receive Ponsegromab only once:
We will measure the amount of the study medicine in the blood of the participants after giving the shots. Later we will examine experiences of people receiving the study medicine. This will help us understand how the medicine is changed and eliminated from your body and to decide if the study medicine is safe. Participants will take part in this study for 22 weeks. During this time, they will stay at the study clinic for the first 8 days and will visit the study clinic about 8 times.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ponsegromab
Drug: Ponsegromab
Participants will receive one subcutaneous injection
Participants will receive four subcutaneous injections
Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Unbound and Total Ponsegromab
AUCinf was defined as area under the serum concentration-time profile from time 0 extrapolated to infinite time.
Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Unbound and Total Ponsegromab
AUClast was defined as area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration.
Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Maximum Observed Serum Concentration (Cmax) of Unbound and Total Ponsegromab
Cmax was defined as maximum observed concentration. Cmax was observed directly from data.
Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Time for Cmax (Tmax) of Unbound and Total Ponsegromab
Tmax was defined as time for Cmax. Tmax was observed directly from data as time of first occurrence.
Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Terminal Half Life (t1/2) of Unbound and Total Ponsegromab
t1/2 was defined as terminal half life. t1/2 was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.
Time frame: Pre-dose, 12, 24, 48, 72, 120, 168 hours after dose on Day 1, Days 10, 15, 29, 50, 71, 93, 106, and 127
Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect.
Time frame: From the first dose of study intervention on Day 1 to Day 127
Number of Participants With Treatment-Related TEAEs and SAEs
AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect. Causality of the TEAEs and SAEs was judged by the investigator.
Time frame: From the first dose of study intervention on Day 1 to Day 127
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
Hematology parameters included hemoglobin, hematocrit, red blood cell, white blood cell and platelet count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean platelet volume, total neutrophils, eosinophils, monocytes, basophils and lymphocytes. Chemistry parameters included blood urea nitrogen, glucose (fasting), calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatinine. Urine parameters included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy. Only those categories in which at least 1 participant had data were reported.
Time frame: From the first dose of study intervention on Day 1 to Day 127
Number of Participants With Clinically Significant Change in Vital Signs
Vital sign measurements included supine blood pressure and pulse rate. Any safety assessments (vital sign measurements) including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator or were considered meeting the AE definition and are listed below.
Time frame: From the first dose of study intervention on Day 1 to Day 127
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)
ECG abnormalities criteria included: 1) maximum QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>30, increase from baseline \>30, \>60; 2) maximum pulse rate (msec): ≥300, baseline \>200 and maximum increase ≥25%, baseline ≤200 and maximum increase ≥50%; 3) maximum QRS (msec): ≥140, increase ≥50%.
Time frame: From the first dose of study intervention on Day 1 to Day 127
| Milestone | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Started | 9 | 9 |
| Completed | 9 | 9 |
| Not completed | 0 | 0 |
AUCinf was defined as area under the serum concentration-time profile from time 0 extrapolated to infinite time.
| nanogram (ng)*day/milliliter (mL) | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Unbound ponsegromab | 109000 ± 58 | 590200 ± 59 |
| Total ponsegromab | 350300 ± 21 | 1105000 ± 44 |
AUClast was defined as area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration.
| ng*day/mL | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Unbound ponsegromab | 95170 ± 55 | 647700 ± 60 |
| Total ponsegromab | 337800 ± 20 | 1036000 ± 42 |
Cmax was defined as maximum observed concentration. Cmax was observed directly from data.
| ng/mL | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Unbound ponsegromab | 4698 ± 41 | 21330 ± 64 |
| Total ponsegromab | 6978 ± 28 | 24910 ± 60 |
Tmax was defined as time for Cmax. Tmax was observed directly from data as time of first occurrence.
| day | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Unbound ponsegromab | 7.01 (5.00 to 14.0) | 5.00 (3.00 to 14.0) |
| Total ponsegromab | 7.01 (3.00 to 14.0) | 6.99 (3.00 to 28.0) |
t1/2 was defined as terminal half life. t1/2 was calculated as Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve.
| day | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Unbound ponsegromab | 8.393 ± 2.8461 | 10.37 ± 3.7287 |
| Total ponsegromab | 23.40 ± 3.8135 | 31.09 ± 8.9457 |
Adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect.
| Participants | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| TEAEs | 4 | 7 |
| SAEs | 0 | 0 |
AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as events that started on or after the first dose but before the end of the study (approximately 18 weeks post dose on Day 1). An SAE was defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect. Causality of the TEAEs and SAEs was judged by the investigator.
| Participants | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| TEAEs | 0 | 1 |
| SAEs | 0 | 0 |
Hematology parameters included hemoglobin, hematocrit, red blood cell, white blood cell and platelet count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean platelet volume, total neutrophils, eosinophils, monocytes, basophils and lymphocytes. Chemistry parameters included blood urea nitrogen, glucose (fasting), calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatinine. Urine parameters included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy. Only those categories in which at least 1 participant had data were reported.
| Participants | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Ery. Mean Corpuscular HGB Concentration (g/dL) >1.1 x upper limit of normal (ULN) | 0 | 1 |
| Mean Platelet Volume (fL) <0.9 x lower limit of normal (LLN) | 4 | 2 |
| Lymphocytes (10^3/mm^3) >1.2 x ULN | 0 | 1 |
| Neutrophils (10^9/L) <0.8 x LLN | 0 | 1 |
| Alanine Aminotransferase (U/L) >3.0 x ULN | 0 | 1 |
| Urate (mg/dL) >1.2 x ULN | 1 | 1 |
| pH (Scalar) <1.0 x LLN | 6 | 5 |
| Ketones ≥1 | 1 | 5 |
| Urine Hemoglobin ≥1 | 1 | 1 |
| Urobilinogen ≥1 | 0 | 3 |
| Leukocyte Esterase ≥1 | 2 | 3 |
| Urine Leukocytes (/uL) >1.0 x ULN | 1 | 1 |
| Epithelial Cells ≥6 | 1 | 0 |
Vital sign measurements included supine blood pressure and pulse rate. Any safety assessments (vital sign measurements) including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator or were considered meeting the AE definition and are listed below.
| Participants | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Number of Participants With Clinically Significant Change in Vital Signs | 0 | 0 |
ECG abnormalities criteria included: 1) maximum QTc interval adjusted according to Fridericia formula (QTcF) (msec): \>450, \>480, \>500, increase from baseline \>30, increase from baseline \>30, \>60; 2) maximum pulse rate (msec): ≥300, baseline \>200 and maximum increase ≥25%, baseline ≤200 and maximum increase ≥50%; 3) maximum QRS (msec): ≥140, increase ≥50%.
| Participants | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) | 0 | 0 |
Collected over From the first dose of study intervention on Day 1 to Day 127. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Ponsegromab 100 mg | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Cohort 2: Ponsegromab 400 mg | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| Event | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/9 | 3/9 |
| COVID-19Infections and infestations | 0/9 | 2/9 |
| Alanine aminotransferase increasedInvestigations | 0/9 | 2/9 |
| Urine leukocyte esterase positiveInvestigations | 0/9 | 2/9 |
| Atrioventricular block first degreeCardiac disorders | 1/9 | 0/9 |
| GingivitisInfections and infestations | 0/9 | 1/9 |
| Animal biteInjury, poisoning and procedural complications | 1/9 | 0/9 |
| Aspartate aminotransferase increasedInvestigations | 0/9 | 1/9 |
| Blood uric acid increasedInvestigations | 1/9 | 0/9 |
| Blood glucose increasedInvestigations | 0/9 | 1/9 |
All enrolled participants who received at least 1 dose of study intervention.
| Age, Continuous(Years) | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg | Total |
|---|---|---|---|
| Median | 34.0 (27 to 54) | 25.0 (21 to 51) | 30.0 (21 to 54) |
| Sex: Female, Male(Participants) | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg | Total |
|---|---|---|---|
| Female | 3 | 1 | 4 |
| Male | 6 | 8 | 14 |
| Race (NIH/OMB)(Participants) | Cohort 1: Ponsegromab 100 mg | Cohort 2: Ponsegromab 400 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 9 | 9 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jan 2023 to primary completion in Jul 2023, 5 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ponsegromab